Search
Carvedilol
go.drugbank.com/drugs/DB01136ApprovedInvestigationalCarvedilol is a racemic mixture where the S(-) enantiomer is both a beta and alpha-1 adrenoceptor blocker, and the R(+) enantiomer is an alpha-1 adrenoceptor blocker. It is currently used to treat heart failure, left ventricular dysfunct...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesLevofloxacin
go.drugbank.com/drugs/DB01137ApprovedInvestigationalLevofloxacin is a fluoroquinolone antibiotic and the optical S-(-) isomer of racemic ofloxacin. It reportedly carries 8 to 128-fold more activity against both gram-negative and gram-positive bacteria compared to R-(+)-ofloxacin and remai...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesSulfinpyrazone
go.drugbank.com/drugs/DB01138ApprovedA uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties.
Categories: Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 SubstratesNefazodone
go.drugbank.com/drugs/DB01149ApprovedWithdrawnNefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury. Drug-induced hepatic i...
Categories: P-glycoprotein inducers, P-glycoprotein inhibitorsDeucravacitinib
go.drugbank.com/drugs/DB16650ApprovedInvestigationalUnlike other Janus kinase 1/2/3 inhibitors that bind to the conserved active domain of these non-receptor tyrosine kinases, deucravacitinib binds to the regulatory domain of TYK2 with high selectivity
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesTebipenem pivoxil
go.drugbank.com/drugs/DB16840ApprovedTebipenem pivoxil is an orally administered prodrug of tebipenem, a carbapenem antibacterial that kills bacteria by binding essential penicillin-binding proteins and disrupting cell wall biosynthesis. Carbapenems are the standard treatme...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 CYP1A2 InducersL-Acetylleucine
go.drugbank.com/drugs/DB16956ApprovedInvestigationalLevacetylleucine (L-acetylleucine) is a modified acetylated derivative of the amino acid leucine. The racemic (i.e. DL-) form has been available in France since 1957 for the treatment of vertigo. Observational studies in patients with Ni...
Categories: P-glycoprotein inhibitorsVorasidenib
go.drugbank.com/drugs/DB17097ApprovedInvestigationalVorasidenib is a first-in-class dual isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor. It works by suppressing the levels of D-2-hydroxyglutarate (2-HG), an oncometabolite produced by mutant IDH1 and IDH2...
Categories: Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 SubstratesAcoramidis
go.drugbank.com/drugs/DB17999ApprovedInvestigationalAcoramidis is a small molecule stabilizer of transthyretin (TTR) for use in patients with TTR amyloidosis. Similar to the previously developed tafamidis, acoramidis is used to stabilize TTR in its tetrameric form, preventing the formatio...
Categories: Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 Enzyme InhibitorsRevumenib
go.drugbank.com/drugs/DB18515ApprovedInvestigationalAbnormal gene rearrangements at chromosome locus 11q23, called KMT2A rearrangements or translocations, are present in 5%-10% of patients with acute leukemias and are the sole genetic aberration found in the majority of infant acute lymph...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Inhibitors